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Abstract: Chronic pain is a devastating condition affecting the physical, psychological, and socioeconomic
status of the patient. Inflammation and immunometabolism play roles in the pathophysiology of chronic
pain disorders. Electrical neuromodulation approaches have shown a meaningful success in otherwise
drug-resistant chronic pain conditions, including failed back surgery, neuropathic pain, and migraine.
A literature review (PubMed, MEDLINE/OVID, SCOPUS, and manual searches of the bibliographies
of known primary and review articles) was performed using the following search terms: chronic pain
disorders, systemic inflammation, immunometabolism, prediction, biomarkers, metabolic disorders,
and neuromodulation for chronic pain. Experimental studies indicate a relationship between the
development and maintenance of chronic pain conditions and a deteriorated immunometabolic state
mediated by circulating cytokines, chemokines, and cellular components. A few uncontrolled in-human
studies found increased levels of pro-inflammatory cytokines known to drive metabolic disorders in
chronic pain patients undergoing neurostimulation therapies. In this narrative review, we summarize the
current knowledge and possible relationships of available neurostimulation therapies for chronic pain
with mediators of central and peripheral neuroinflammation and immunometabolism on a molecular
level. However, to address the needs for predictive factors and biomarkers, large-scale databank driven
clinical trials are needed to determine the clinical value of molecular profiling.
Int. J. Mol. Sci. 2019, 20, 4737; doi:10.3390/ijms20194737 www.mdpi.com/journal/ijms
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1. Introduction
The estimated prevalence of chronic pain varies between 20–40% and is characterized by an
increased socioeconomic burden negatively affecting both the physical condition and quality of life of
patients [1]. Chronic pain conditions pose very high costs of treatment worldwide. The estimated
costs (National academic press, USA) of pain treatments ranged between US$ 560–635 billion in 2010.
Clearly, the recent opioid crisis demonstrated the need to replace former treatment strategies for chronic
pain disorders with non-opioid pharmacological paradigms and neurostimulation therapy.
Chronic pain, as a consequence of tissue injury, is characterized by activation and sensitization
of central and peripheral pain pathways mediated through multiple inflammatory molecules
including leptin, its relatives adiponectin and ghrelin, interleukin (IL) IL1-β, tumor necrosis factor
TNF-α, IL-6, high-mobility group box-1 HMGB-1, damage-associated molecular pattern DAMP´s,
oxytocin, and multiple chemokines, reactive oxygen species, ATP, lipids, and vasoactive amines.
Neuropathic pain is initiated by a lesion in the somatosensory nervous system, is strongly associated with
neuroinflammation, and is considered a more severe form of pain that also influences sleep quality and
psychological functioning [2]. Experimental studies suggest that these inflammatory peptides including
adipocytokines interact with neural transmission by promoting hyperexcitability in neural circuits
relevant for the development of chronic pain disorders (e.g., spinal cord dorsal column, dorsal root
ganglia, and trigeminal ganglion). For instance, Il-1 β and leptin (pro-inflammatory) and oxytocin
(anti-inflammatory) exert their effects through specific receptors located either at the terminal C-fibers
(neuropathic pain) or the trigeminal ganglion (migraine). Pharmacological treatment with a variety of
classes of drugs and behavioral therapy are first-line treatments for neuropathic pain [3–8], but many
patients fail to experience clinically meaningful pain relief from these treatments alone. Drug resistance
and loss of efficacy in chronic pain treatment are perhaps due to the involvement of multiple disturbed
physiological and psychological interrelated pathways that contribute to the severity of chronic pain.
Hence, understanding mechanisms of relevant comorbidities underlying chronic pain (e.g., metabolism,
depression, and anxiety) may help to develop novel diagnostic and treatment options. In addition
to their role in the transition and maintenance of chronic pain, most of the described mediators have
been associated with a broad range of chronic disorders (neurological, psychiatric, cardiovascular,
and metabolic) due to their multifunctional characteristics, which in turn may explain the clinically
observed co-occurrence of the so-called comorbidities [9–12]. Spinal and peripheral neurostimulation
therapies have repeatedly shown meaningful pain relief in recent studies to treat various chronic pain
disorders (failed back surgery, complex regional pain syndrome (CRPS), and migraine) targeting the
spinal cord, the dorsal root ganglia (DRG), and peripheral nerves (vagus nerve stimulation; VNS) [3–8].
The strongest rationale for considering neurostimulation approaches to treat chronic pain is the growing
understanding that all forms of pain are ultimately the result of an interplay of central and peripheral
properties of the nervous system, which in turn allows neurostimulation therapies to interact with
inflammatory pain signaling [13–18]. Although psychometric alterations (depression, cognitive decline,
and anxiety) and functional parameters such as sleep or metabolic state have been reported to interact
with neurostimulation responsiveness, objective and quantitative outcome measures on a molecular
level remain largely under-investigated. The majority of published studies assess neurostimulation
outcomes using subjective score-based tools [18]. In this narrative review, we provide experimental
evidence and describe the current state of in-human studies assessing possible relationships between
the responsiveness of neurostimulation therapies for chronic pain and molecular profiling of circulating
mediators relevant for functional metabolic homeostasis including leptin and its relatives adiponectin
and ghrelin, and other associated mediators of metabolic-related inflammation.
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2. Methods
Search strategies encompassed published literature identified through searches of PubMed,
MEDLINE/OVID, and SCOPUS and manual searches of the bibliographies of original and review
articles from 2000–2019 with the following terms: chronic pain disorders, systemic inflammation,
immunometabolism, adipokines, cytokines, chemokines, biomarkers, metabolic disorders,
neuromodulation for chronic pain, and in-human studies to identify primary outcome
measures using molecular profiling of inflammation. The primary criteria for inclusion in our
review were the following terms: chronic pain disorders—neurostimulation therapies—human
studies—inflammatory phenotyping.
3. The Role of Circulating Inflammatory Mediators in Chronic Pain Development
Cytokine and chemokine mediated inflammation is an essential aspect of the pathophysiological
processes of pain. Evidence from clinical and pre-clinical data support the notion that pro-inflammatory
cytokines including IL-1β, TNF-α, and chemokines such as monocyte chemotactic protein-1 (MCP-1)
directly modulate cell activity in different types of neural cells both in the peripheral and central nervous
systems (PNS and CNS respectively) [19–23]. In the PNS, topical application of TNF-α to the peripheral
axons evoked abnormal spontaneous activity from nociceptive neurons [20]. In a similar manner,
TNF-α application to the somata of the DRG neurons in vitro provoked abnormal spontaneous activity.
Moreover, large myelinated fast-conducting Aβ neurons specifically are excited by topical application
to the DRG of TNF-α or by an autologous herniated nucleus pulposus extract [21]. Interestingly, TNF-α
can enhance the sensitivity of sensory neurons to the excitation produced by capsaicin, and this
enhancement likely is mediated by the neuronal production of prostaglandins [20]. Mechanistically at
the level of cellular signals, TNF-α-induced neuronal excitation is mediated by the cAMP-dependent
protein kinase (PKA) pathway [20]. The p38 mitogen-activated protein kinase (MAPK) is also
involved in TNF-α-induced cutaneous hypersensitivity to mechanical or thermal stimulation [24].
Interestingly, the data from IL-6 knockout mice indicate that IL-6 plays a facilitating role in sympathetic
sprouting induced by nerve injury, and its effect on pain behavior is promoted through sympathetic
sprouting in the dorsal root ganglia [25]. Consistent with the above data, localized inflammation of the
DRG up-regulates a number of pro-inflammatory cytokines including IL1-β, IL-6, TNF-α, HMGB-1,
DAMP´s, oxytocin, multiple chemokines, reactive oxygen species, ATP, lipids, and vasoactive amines
induces abnormal sympathetic sprouting in the absence of peripheral nerve injury [26]. It suggests
a possible correlation between inflammatory responses and sympathetic sprouting, which are two
well-known mechanisms implicated in various chronic pain states. This data taken together shows,
pro-inflammatory cytokines to be involved in the pathophysiology of the development of inflammatory
and neuropathic pain with intense sympathetic nervous system involvement. Hence, specific cytokines
and their neutralizing antibodies could be utilized locally or systemically to block pro-inflammatory
cytokines for the treatment of chronic pain. These specific antibodies against pro-inflammatory
cytokines would act to disrupt the hyperexcitability cycle taking place in the sensory neurons and hence
may provide a new, non-NSAR, non-opioid therapeutic approach for the treatment of pathological pain
due to inflammation or peripheral nerve injury. Neurostimulation therapies (non-invasive–invasive)
targeting different neural targets are successfully being used in clinical pain medicine, but their mode of
action and their interaction with cellular and molecular properties of the neuro-immune axis in humans
has been poorly investigated, but would probably have a considerable diagnostic and therapeutic yield
for pharmacological and non-pharmacological (neurostimulation) approaches (Scheme 1).
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Scheme  1.  Mediators  of  inflammation  and  immunometabolism  determined  in  human 
neurostimulation studies for chronic pain [8–10,27–33]. 
3.1. Possible Associations between Back Pain (Spino‐Nociceptive Traffic) with Immunometabolism 
Experimental  and  in‐human  studies  indicate  that  obesity  and  associated  diseases  such  as 
diabetes or cardiovascular disorders (heart failure, stroke, and cerebral ischemia) can be regarded as 
a consequence of ongoing chronic inflammation. However, both preclinical and human trials have 
often  been  contradictory  in  assessing  the  relationships  between  low  back  pain  and  chronic 
inflammation  [27–32].  In  part, metabolic  disorders  and  related  comorbidities  have  gaped  to  the 
development of  low back pain  indicative of an  imbalanced brain–immune communication, which 
could promote central and peripheral inflammation [32–34]. The complex interplay of pro‐ and anti‐
inflammatory cytokines  (e.g.,  IL‐6,  IL‐10,  IL‐13,  tumor‐necrosis  factor  (TNF‐α), and oxytocin) and 
other pro‐ and anti‐obesity‐relevant peptides, especially leptin (LP), adiponectin (AN), and ghrelin 
(GH), are thought to evoke the genesis and maintenance of both chronic conditions (pain–metabolic 
disorder)  [28,32–39]. Notably,  immunoregulatory  IL‐10, TNF‐α, and  IL‐1 have been  linked  to  the 
pathophysiology  of  multiple  chronic  disorders  including  pain,  obesity,  diabetes,  metabolic 
syndrome, and depression/anxiety, most of which are frequently observed clinically [6,7,34,40]. 
In  this  context,  a principal member of  the  adipokine  superfamily,  leptin  (LP), derived  from 
adipocytes, vascular smooth muscle cells, and cardiomyocytes, represents one of the key players in 
favor of an obese state with studies supporting the relationship between LP expression and body fat 
mass [34,41,42]. Contrary to IL‐10, elevated LP concentration may predict the development of obesity, 
myocardial ischemia, heart failure, and insulin resistance on the one hand. Clearly, chronic pain is 
fraught frequently with obesity, but not in general; hence leptin and relatives should be integrated 
into chronic pain assessment on the other hand as LP drives IL‐1 synthesis, which in turn promotes 
a chronic pain state [34]. Contrary, decreased concentrations of adiponectin (AN), another member 
of the adipokine family and a neuropeptide solely synthetized by adipocytes, has been suspected of 
inducing  metabolic  disorders  (e.g.,  type  2  diabetes,  arterial  hypertension,  and  coronary  artery 
disease). Whether concentration changes in circulating AN relate to changes in body weight (body 
mass  index; BMI) or only  represent an  epiphenomenon  is  still  largely unknown  [4–6,41–43]. AN 
affects  the resistance of  insulin receptors  (anti‐diabetic effect),  lipid oxidation, vasodilatation, and 
anti‐arteriosclerosis effects [34,41,42]. To generate an estimated risk profile for metabolic disorders, 
some  studies  used  the  LP–AN  ratio  (LAR)  rather  than  LP  or  AN  quantification  alone.  The 
neuropeptide  ghrelin  (GH)  promotes  lipolysis  and protects  the  vascular  endothelial  architecture 
(vasoconstriction‐suppression) effects. GH is synthesized in the stomach and binds to receptors in 
the central hypothalamus to stimulate the appetite. Clinical studies have indicated that GH levels are 
positively  correlated with  body  fat mass. Decreased GH  concentrations were  detected  in  obese 
individuals compared to non‐obese controls. Thus, the relationships between chronic low back pain, 
Scheme 1. Mediators of inflammation and immunometabolism determined in human neurostimulation
studies for chronic pain [8–10,27–33].
3.1. Possible Associations between Back Pain (Spino-Nociceptive Traffic) with Immunometabolism
Experimental and in-human studies indicate that obesity and associated diseases such as
diabetes or cardiov scular disorders (heart failure, stroke, and cerebral ischemia) can b regarded
as a consequence of ongoing chronic inflammation. However, both preclinical d hum n trial
have often been c tradictory in assessing he relationships betw en low back pain and chronic
inflammation [27–32]. In part, metabolic disorders and related com rbidities have gaped to the
development of low back in indicative of an imbalanced brain–i mune communication, which
could romote central and per pher l inflammation [32–34]. The co pl x interplay of pro- and
anti-inflammatory cytokines (e.g., IL-6, IL-10, IL-13, tumor-necrosis factor (TNF-α), and oxytocin) and
other pro- and anti-ob ity-relevant peptides, especially leptin (LP), adiponectin (AN), and ghrelin
(GH), a e thought to evoke the genesis and maintenance of both chronic c di ons (pain–metabolic
disorde ) [28,32–39]. N tably, immunoregulatory IL-10, TNF-α, and IL-1 have been li ked to the
pathophysiology of multiple chronic disorders including pain, obesity, diabetes, metabolic syndrom ,
and depression/anxiety, most of which are frequ ntly observed clinically [6,7,34,40].
In this context, a principal me ber of t e adipokine superfamily, leptin (LP), derived from
adipocytes, vascular smooth muscl cells, and car iomyocytes, represents one of the key players in
favor of an obese state with studies supporting the relati nship b tw en LP expression and body fat
mass [34,41,42]. Con rary to IL-10, elevated LP concentration may predict the dev lopment of besity,
yocardial ischemia, heart failure, and insulin resistance on the one hand. Clearly, chronic pain is
fraught frequently with obesity, but ot i ge e al; he leptin and relatives should be integrated
into c ronic pain assessment on the other hand as LP drives IL-1 synthesis, which in turn promot s
a chronic pain state [34]. Contrary, decr ased concentrations of adipon ctin (AN), another memb r
of t e adipokine family and a neurop ptide solely synthetized by adipocytes, has been suspected of
inducing metabolic disorders (e.g., ty 2 iabet s, arterial hypertension, and coronary artery dis ase).
Whether concentration changes in circulating AN r late to changes in body weight (body mass index;
BMI) or only represent an epiphenomenon is still largely unknown [4–6,41–43]. AN affects the resistance
of insulin receptors (anti-diabetic effect), li id oxidation, vasodilatation, and a ti-arteriosclerosis
eff t [34,41,42]. To generate an estimated risk profile for metabolic disorders, some studies use
the LP–AN rati (LAR) rather than LP r AN quantification alone. The n uropeptide ghrelin (GH)
promotes lipolysis and protects the vascular endot lial architectu e (vasoconstri tion-suppr ssion)
effects. GH is synthesized in the stomach and binds t receptors in the c tral hypothalamus to
stimulate the appetite. Clinical studies have indicated that GH lev l are positively correlated with body
fat mass. Decreased GH concentrations were det cted in obese individuals ompared to non-obes
Int. J. Mol. Sci. 2019, 20, 4737 5 of 15
controls. Thus, the relationships between chronic low back pain, a very common spinal-nociceptive
issue, and immune-driven metabolic disorders appear to be intricately intertwined [44–49].
3.2. Possible Associations between Migraine (Trigemino-Nociceptive Signaling) with Immunometabolism
There is increasing evidence that migraine, a neurological disorder of the trigeminal-nociceptive
system, is associated with the contribution of adipose tissue cellular components of systemic
inflammation. Circulating mediators of inflammation involved in the mechanisms of migraine
pathology are secreted from adipocytes and adipose tissue-derived immune cells [4]. It is widely
recognized, white adipose tissue (WAT), an endocrine-active organ, not only functions as a site of
energy storage but also has the capability to exacerbate or reduce systemic inflammation. Within WAT
there is a complex interplay between adipocytes involving the balance of synthesis of LP and AN,
and the neuro-immune axis to essentially establish physiological homeostasis which, if dysfunctional,
leads towards obesity and drives cascades of neuroinflammatory mediators that impact many
of the neural circuits relevant to migraine [50,51]. LP (pro-inflammatory), a metabolic marker
produced by WAT cells drives COX-2 related pathways of IL-1β in glial cells and neurons of the
hypothalamic–pituitary axis. Additional experimental work demonstrated that ghrelin improved light
sensitivity, an indicator for migraine-related autonomic features, and evoked behavioral changes in an
experimental animal model of head pain [51].
3.3. Oxytocin at the Crossroad of Trigeminal-Spinal Pain Transmission and Immunometabolism
Preclinical as well as human studies indicate that the neuropeptide oxytocin impacts pain
perception and processing of both the trigemino-nociceptive (e.g., migraine) and the spino-nociceptive
(neuropathic pain) systems [52–68]. In addition, oxytocin interacts with metabolic neural circuits and
metabolic-related organ systems (liver, muscle, adipose tissue, and pancreas) [53]. The magnocellular
neurons located in the hypothalamic nuclei PVN (nucleus paraventricularis) and the SOP
(supraoptic nucleus) synthesize oxytocin, which is transmitted in vesicles via anatomical projections
to the posterior pituitary lobe, the amygdala, the hippocampus, and the cerebral cortex, ultimately
promoting oxytocin release into the systemic blood circulation. A second population of parvocellular
oxytocinergic neurons in the PVN projects directly to the brainstem and the spinal cord (dorsal column
layers–dorsal root ganglion) without the involvement of the systemic blood circulation [54–56].
Based upon available evidence, oxytocin appears to negatively impact nociceptive transmission and
signaling in all these areas directly, via on-site neuronal delivery, or indirectly, via the blood circulation,
thereby regulating both central and peripheral inflammatory processes.
Experimental animal models and in-human studies have shown positive analgetic effects of
oxytocin on cephalgia. After administration of radiographic labeled oxytocin, high concentrations were
recorded in the trigeminal nucleus caudalis, the trigeminal ganglia, and the trigeminal branches [57,58].
In addition, several uncontrolled cohort trials observed a meaningful head pain reduction in
migraineurs after oxytocin administration. So far, evidence suggests oxytocin may be involved
in central sensitization and autonomic dysregulation, conditions frequently observed in migraine
phenotypes [59–61]. As mentioned, oxytocin projects directly via descending neural routes to specific
neuronal cell layers of the spinal cord (dorsal horn laminae) and in addition, is able to bind to receptors
of the dorsal root ganglia neurons (DRG) (Scheme 2). This may explain the anti-nociceptive effects of
oxytocin in spino-nociceptive circuits elated to pain processing [5–7,64–68].
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Scheme 2. Oxytocinergic descending hypothalamic-spinal circuit promotes anti-nociception and
analgesia. Oxytocin is synthesized in neurons located within the hypothalamic nuclei (nucleus
paraventricularis of the hypothalamus; PVN) and the supraoptic nucleus (SOP). Magnocellular
neurons are distributed in the PVN and in the SOP and project to the posterior pituitary lobe,
where oxytocin is released into the systemic blood circulation and impact neural transmission of
the amygdala and hippocampus. Parvocellular oxytocinergic neurons (PVN) release oxytocin in
the brainstem, spinal cord, and trigeminal ganglion [5,52,54–58]. Abbreviations: PNV—nucleus
paraventricularis; SOP—supraoptic nucleus; SCDC—spinal cord dorsal column; DRG—dorsal
root ganglion; GABA—gamma aminobutyric acid; CGRP—calcitonin-gene related peptide;
COX—cyclooxygenase; PG—prostaglandine.
Metabolic disorders frequently co-occur in chronic pain, independently of the pain origin,
leading to the question of what role oxytocin may play in metabolic hemostasis under chronic pain
conditions. Currently, the hypothalamic–pituitary axis has been recognized as a potential target to
restore metabolic function and to impact chronic pain-associated neural transmission, either directly
(neuronal) or indirectly (systemic blood circulation). In particular, this becomes an important issue,
if clinical phenotypes (pain-metabolism) become difficult to distinguish on a molecular level. It appears
that both common and different pathways exist, but this notion is still to be elucidated. Consequently,
clinical neurostimulation studies should seek to incorporate metabolic-related markers with the
potential to predict chronic pain by diagnostic means. For instance, intranasal administered oxytocin
reduced weight, improved insulin sensitivity, and increased pancreatic responsivity in small-scale
studies [53]. However, in opposition to what is seen in human trials with apparent conflicting findings,
experimental animal studies suggest that oxytocin impacts glucose uptake and lipid utilization in
muscle and adipose tissue. This suggests a deterioration in oxytocin signaling may exacerbate obesity
and related vascular disorders.
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4. Clinical Implications for Neurostimulation Therapies Targeting Chronic Pain Disorders
Possible pathways through which central and peripheral neuromodulation may impact circulating
markers of immunometabolism are largely under-investigated in clinical neuromodulation trials.
These mechanisms are not likely to be specific for single cytokines, but more likely help control
inflammation in quite diverse inflammatory disorders, by activating multiple neuronal networks
to control immune cells and thereby minimize the detrimental effects of excessive inflammation
seen in chronic pain, dysfunctional metabolism, stroke, epilepsy, and psychiatric disorders.
However, the mechanisms of inflammatory action of the applied central and peripheral electrical
stimulation modalities (e.g., SCS, DRG, VNS, non-invasive, and invasive brain stimulation) have
yet not been fully clarified. A large number of experimental VNS studies have been published
which indicate VNS controls the release of multiple cytokines from peripheral macrophages
through the neuro-inflammatory reflex involving the nicotinic acetylcholine receptor (nACh) α7.
The neuro-inflammatory reflex is in part orchestrated by the dynamic and complex interaction of pro-
and anti-inflammatory mediators (e.g., IL-1β, IL-6, IL-8, IL-10, IL-13, interferon-g (IFN-g), TNF-α,
and HMGB-1 protein) [69–73]. Combined electrical stimulation of the sciatic nerve and the vagal nerve
was found to increase plasma levels of circulating oxytocin as well as touch and pinch indicating
the potential of targeted neurostimulation to evoke changes in molecular circuits relevant for pain
and metabolism [71]. Given these facts, VNS has been applied for a variety of inflammatory pain
disorders (primary headache disorders, rheumatoid arthritis, chronic back pain, neuropathic leg pain,
complex regional pain syndrome, chronic pelvic pain, and fibromyalgia) [74].
5. In-Human Chronic Pain-Neurostimulation Studies Addressed to Metabolic Molecular
Inflammatory Phenotyping (Cervical Non-Invasive VNS, Tonic and BurstDR SCS, DRG-SCS)
To date, there exist a few randomized-controlled and uncontrolled observational neurostimulation
human studies, which have quantified peripheral circulating markers of inflammation related to
metabolic homeostasis in chronic pain patients [4–7,75–79] (Table 1).
Most recently, a randomized sham-controlled VNS migraine study [4] found most of the inter-ictal
measured cytokines including IL-6, TNF-α, and HMGB1 unchanged before and after VNS as were the
metabolic markers leptin, ghrelin, and adiponectin, although serum concentrations were higher in
migraine subjects compared to healthy controls. Pro-inflammatory IL-1β plasma concentrations were
higher in the sham-VNS group versus the verum nVNS, whereas anti-inflammatory cytokine IL-10
was elevated in migraine patients as compared to healthy subjects but was suppressed three months
post-stimulation in both sham and VNS group. These effects were accompanied by a significantly
reduced number of severe attacks per month in the nVNS group. Notably, the average BMI was
below 25 m2/kg, yet nearly 45% of the study cohort suffered from a metabolic-associated disorder
(hypertension, cardiac disease) [4]. In a different recent study, significantly increased saliva levels
of anti-inflammatory oxytocin and pro-inflammatory IL-1β were detected in the saliva of migraine
patients treated before and after VNS treatment, while obesity was present in only 30% of the cohort [52].
In another study including solely healthy subjects, VNS significantly reduced serum IL-1β, TNF- α,
IL-6 IL-8, macrophage inflammatory protein [MIP]-1α, and monocyte chemoattractant protein [MCP]-1
demonstrating the anti-inflammatory impact of VNS [80].
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Table 1. In-human neurostimulation trials for chronic pain disorders addressed to molecular phenotyping, including markers relevant for immunometabolism.
Year/Study
Design
Pain
Disorder
Stimulation
Target Patients
Score-Based
Parameter Stimulation Paradigm Immunometabolic Parameter
Treatment
Duration
2019/RCT [4] Migraine
Cervical branch
vagus nerve
(nVNS)
[48]
Head pain
Severity-Frequency,
BMI, PSQI,
MIDAS, BDI
120 sec dose bilateral vagus
nerve applied 2 times/day (1
ms bursts of 5 kHz sine
waves every 40 ms (25 Hz))
ELISA serum (leptin, ghrelin,
adiponectin, IL-1β, IL-6, IL-10, TNF-α,
HMGB-1)
2 months
2019/pPS [52] Migraine
Cervical branch
vagus nerve
(nVNS)
[24]
Head pain Severity
-Frequency, BMI,
PSQI, MIDAS, BDI,
EQ-5D-5L
120 sec dose bilateral vagus
nerve applied 2 times/day (1
ms bursts of 5 kHz sine
waves every 40 ms (25 Hz))
ELISA saliva (IL-1β – oxytocin) 10 weeks
2019/pPS [5] CRPS DRG(L4-DRGSTIM)
[24]
Neuropathic pain
Severity, BMI,
PSQI, BDI
Chronic stimulation,
bipolar, 20 Hz, 200-300 µsec,
300–1600 µA
ELISA serum-saliva (leptin, ghrelin,
adiponectin, IL-1β, IL-6, IL-10, TNF-α,
HMGB-1, BDNF, oxytocin)
3 months
2019/pPS [79] CRPS DRG(L4-DRGSTIM)
[12]
Neuropathic pain
Severity, BMI,
PSQI, BDI
Chronic stimulation,
bipolar, 20 Hz, 200–300 µsec,
300–1600 µA
Gene expression blood cells (FFAR2,
ILRN, IL-17F, PLA2G2, NOX1 (metabolic
function))
3 months
2018/pPS [6] FBSS CLBP
Spinal Cord dorsal
column level
Th10-11
[24]
FBSS-CLBP
Severity, BMI,
PSQI, BDI
BurstDR chronic
stimulation, bipolar, 40 Hz
burst rate, 500 Hz intraburst
rate, 1 msec, 2.05–2.45 mA
ELISA-serum (leptin, adiponectin,
ghrelin) 3 months
2017/pPS [7] FBSS CLBP
Spinal Cord dorsal
column level
Th10-11
[24]
FBSS-CLBP
Severity, BMI,
PSQI, BDI
BurstDR SCS chronic
stimulation, bipolar, 40 Hz
burst rate, 500 Hz intraburst
rate, 1 msec, 2.05–2.45 mA
ELISA-serum (IL-1β, IL-10, TNF-α,
HMGB-1) 3 months
2017/RCT [78] CRPS
Spinal Cord dorsal
column level
Th10-11
[24]
CRPS Severity –
Phenotype FBSS –
CLBP Severity,
BMI, PSQI, BDI
SCS chronic stimulation,
bipolar, BurstDR vs 40 Hz
vs 500 Hz vs 1200 Hz vs
sham
ELISA-artificial skin blister (IL-1b, IL-1ra,
IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9,
IL-10, IL-12p70, IL-13, IL-15, IL-17, basic
FGF, Eotaxin, G-CSF, GM-CSF, IFN-g,
IP-10, MCP-1, MIP-1a, MIP-1b, PDGF-BB,
TNF-a, VEGF, T cells)
3 months
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Table 1. Cont.
Year/Study
Design
Pain
Disorder
Stimulation
Target Patients
Score-Based
Parameter Stimulation Paradigm Immunometabolic Parameter
Treatment
Duration
2016/pPS [75]
NP
Phantom
pain
Spinal Cord dorsal
column level
Th10-11
[14] Pain Severity BMI
Chronic stimulation,
bipolar, tonic SCS mode
with 50 Hz SCS on vs off
Proteomic Mass Spectrometry-CSF
(clusterin, gelsolin, mimecan,
angiotensinogen, secretogranin-1,
amyloid beta A4 protein, gelsolin,
apolipoprotein C1, apolipoprotein E,
contactin-1, neural cell adhesion
molecule L1-like protein, VGF and
dickkopf-related protein 3)
12 months
2014/pPS [77] FBSS
Spinal Cord dorsal
column level
Th10-11
[9] Pain Severity,SF-36
Chronic stimulation, bipolar,
tonic SCS mode with 40–100
Hz, 210–360 µsec, 3–7.4 Volt
ELISA-CSF (GDNF)
2013/pPS [76]
NP
Phantom
pain
Spinal Cord dorsal
column level
Th10-11
[14] Pain Severity,SF-36
Chronic stimulation, bipolar,
tonic SCS mode with 40–100
Hz, 210–360 µsec, 3–7.4 Volt
ELISA-CSF (VEGF, BDNF, MCP-1,
chemokines)
CM = chronic migraine; EM = episodic migraine; HFEM = high frequency episodic migraine; FBSS = failed back surgery syndrome; CLBP = chronic lower back pain; CRPS = complex
regional pan syndrome; NP = neuropathic pain; VAS = visual analogue scale; HIT = Headache Impact Test; m = month; MIDAS = migraine disability score; BDI = beck depression
inventory, PSQI = Pittsburgh Sleep Quality Index; BMI = body mass index; EQl = Quality of life; nVNS = cervical non-invasive vagus nerve stimulation; SCS = tonic spinal cord stimulation;
BurstDR-SCS = burst spinal cord stimulation; DRG-SCS = dorsal root ganglion stimulation; CSF = cerebrospinal fluid; IL = interleukines, HMGB-1 = high-mobility group box-1; DAMP´S =
damage-associated molecular pattern; free fatty acid receptor 2 (FFAR2); interleukine receptor 1 antagonist (ILRN), interleukine 17-F (IL-17F); phospholipase A2, group IIA (PLA2G2);
NADPH oxidase (NOX1); VEGF = vascular endothelial growth faxtor; GDNF = glial cell-derived neurotrophic factor; ELISA = enzyme-linked immune assay; pPS = prospective pilot
study; rCS = retrospective case series; RCT = randomized, double-blind sham-controlled study; w = week; y = year.
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Other observational studies and randomized, double-blinded sham-controlled trials have
assessed the influence of SCS using tonic waveforms on inflammatory molecular profiles targeting
cerebrospinal fluid or skin blister fluid in patients with chronic nociceptive low back and neuropathic
leg pain. Inflammatory measures included vascular endothelial growth factor (VEGF), brain-derived
neurotrophic factor (BDNF), monocyte chemotactic protein-1 (MCP-1), IL-2, IL-6, IL-12, IL-15, IL-17,
TNF-α, interferon-γ (INF- γ), and cellular ratio (Th1-Th2), of which some were changed after
conventional, low-frequency SCS (tonic waveform). Although leptin and related metabolic markers
were not included, nor were a systematic assessment of weight and/or the existence of metabolic
disease performed, some of the measured cytokines and chemokines have been noted in the context of
metabolic diseases and depression [75–78].
In non-obese, failed-back-surgery syndrome patients (FBSS) treated with BurstDR, circulating
anti-inflammatory IL-10 was significantly increased after stimulation, while leptin was significantly
higher at the baseline with a trend towards lower levels after stimulation. Adiponectin and
ghrelin remained unchanged before and after stimulation compared to the healthy control group.
Although the study subjects were classified as non-obese according to the BMI, diabetes, hypertension,
and cardiovascular disorders were highly prevalent among those subjects with depressive symptoms
and disturbed sleep [6,7].
In complex regional pain syndrome (CRPS) and associated comorbidities, a pro-inflammatory state
driven by different mediators which results in the complex phenotypes of CRPS may present. In a study
of unilateral, targeted dorsal root ganglion stimulation (spine level L-4), improvements were noted in
neuropathic pain intensity, sleep quality, and mood in pre-obese CRPS subjects (BMI 29 ± 5.6 kg/m2).
The choice to study unilateral selective L4 DRG was based on the fact that the knee sensorial innervation
is made mainly by this spinal nerve. We believed that if L3 or L5 DRGs were also added, it would have
been more difficult to achieve a more precise change, but could not exclude the fact that multisegmental
DRG-stimulation would have promoted different changes. Each study subject in this study was
noted to have one or more of the following immuno-metabolic clinical disorders: hypertension,
diabetes, or cardiac ischemia. On a molecular level, significantly increased serum concentrations
of leptin, high-mobility group box 1 (HMGB-1), TNF- α, and IL-6 were quantified before and after
L4-DRG stimulation, while IL-1β was significantly increased pre-stimulation, but not after L4-DRG
stimulation, and pre-stimulation levels of increased IL-10 were noted to significantly decrease after
DRG stimulation. Adiponectin and ghrelin did not differ between CRPS patients and healthy controls at
baseline and follow-up [5]. In an extended subgroup assay, the gene expression profile revealed several
significantly up- and down-regulated genes. Despite their function for inflammatory host response
and neural nociceptive excitability and traffic, some of the genes assessed from the CRPS patients like
free fatty acid receptor 2 (FFAR2); interleukin receptor 1 antagonist (ILRN), interleukin 17-F (IL-17F);
phospholipase A2, group IIA (PLA2G2); and NADPH oxidase (NOX1) have been associated with
metabolic function such as glucose hemostasis, response to starvation, insulin resistance, lipid catabolic
function, angiogenesis, blood pressure, and metabolic functions [79]. With regards to CRPS, caution is
needed due to the protean nature of CRPS over time and varying phenotypes. CRPS patients remain
unique in their presentation and their clinical features. Depending on the time relationship within the
inflammatory process, a specific immunological target can change its role by transitioning from the
innate to the adaptive immune response. According to the phenotype, the immunological target can
vary in role, being either a critical key link in the initiation of the disease or be an inducible marker
as the disease progresses associated with a broad variety of physical features such as trophic skin,
vascular changes to metabolic factors, bone turn over, trophic skin changes to dystonia [81].
This leads to the conclusion that neuromodulation approaches (waveforms) may need to be
different (tonic, burst, frequency-regulated) at different times depending upon the effects it can have
on chronic pain and relevant comorbidities in balancing the neuro-immune axis (Scheme 1).
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6. Conclusions and Future Targeted Research
Beyond doubt, this narrative review did not cover the entire spectrum of molecular mediators
involved in immunometabolism and inflammation but rather attempted to provide a comprehensive
review of inflammatory markers assessed in clinical human neurostimulation trials for chronic pain.
Obviously, the pathophysiology of the chronic pain disorders (migraine, CRPS, CLBP, and FBSS)
and the approached neural target reported in our review differ fundamentally but may have some
overlap in relevant comorbidities such as metabolic disease. In view of the provided data, it appears
that molecular profiling of circulating markers of immunometabolism has been under-appreciated
and deserves enhanced clinical research attention in the study of patients with chronic pain being
treated with neurostimulation therapy. The broad variety of clinical phenotypes observed in chronic
pain syndromes and associated comorbidities, of which metabolic-associated disorders are one major
representative, points to the urgent need of translational neurostimulation research considering leptin
and its related biomarkers of immunometabolism, adiponectin, and ghrelin along with molecular
and cellular promoters of neuroinflammation. Hence, a multiplex analysis should be considered via
both flow cytometry and mass cytometry techniques to properly determine both extracellular and
intracellular changes. These approaches may be complemented by computational tools (computational
neurosciences) [82].
To address these translational issues, randomized-controlled neurostimulation trials for chronic
pain using a standardized pre-analytic protocol (sample storage, assay, and processing techniques),
considering potential bias (age, gender, epigenetic/genetic, and environmental factors) and accompanied
by experimental studies are highly warranted.
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